1. Scrip
  2. >>Business
  3. >>Strategy

Israel's BiondVax To Take 'More Global View' With NASDAQ-Only Listing

 
• By Sten Stovall

BiondVax's CEO tells Scrip why the Israel-based vaccine maker wants to delist there and only have a US-based NASDAQ listing and re-make its executive board in to one that's more internationally experienced.

Nasdaq
BiondVax Says Being Soley NASDAQ-Listed Will Help Make It More Internationally-Minded • Source: Shutterstock

BiondVax Pharmaceuticals Ltd. wants to "spread its wings" now that it is adequately funded to progress its lead flu vaccine candidate – but to do that BiondVax feels it must delist from the Tel Aviv Stock Exchange while maintaining a continued listing on NASDAQ, and rebuild its executive board into one that is more commercially minded.

"We are now ready to concentrate our attention on just one exchange as we move forward," Ron Babecoff, BiondVax's CEO...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

More from Business

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.